Therapeutics | StudyLocation | StudyDesign | PatientsNumber (n) | Patients MeanAge (years) | ICU Admission | MechanicalVentilation | Recovery | Mortality | Reference |
Hydroxychloroquine 14(100%) | France | Prospective | 14 | 51.2 | NA | NA | 8 (57.1%) | NA | Gautret et al2020 |
Hydroxychloroquine 6(100%) Azithromycin 6(100%) | France | Prospective | 6 | 51.2 | NA | NA | 6 (100%) | 0 |
Oseltamivir 18(100%) Antibiotics 18(100%) Corticosteroid 11(61.1%) | China | Retrospective | 18 | NA | 18 (100%) | 6 (33.3%) | NA | 17 (94.4%) | Cao J. et al 2020 |
Favipiravir 116(100%) | China | Prospective | 116 | NA | NA | 21 (18.10%) | 71 (61.20%) | NA | Chen et al 2020 |
Umifenovir 120(100%) | China | Prospective | 120 | NA | NA | 27 (22.50%) | 62 (51.67%) | NA |
Interferonα-1b Amoxicillin | China | Casereport | 1 | 55-day-old | 1 (100%) | 1 (100%) | 1 (100%) | 0 | Cui Y. et al2020 |
Vancomycin Remdesivir | USA | Casereport | 1 | 35-year-oldman | 0 | 1 (100%) | 1 (100%) | 0 | Holshue et al2020 |
Oseltamivir 38(93%) Antibiotics 41(100%) Corticosteroid 9(22%) | China | Prospective | 41 | 49 | 13 (32%) | 12 (29%) | 28 (68%) | 6 (15%) | Huang C. et al2020 |
Umifenovir50(83.3%) Lopinavir +Ritonavir 41(68.3) Interferon 12(20%) Ribavirin 7(11.7%) Oseltamivir 2(3.3%) Glucocorticoid34(56.7%) Immunoglobulin 28(46.7%) Antibiotic therapy 56(93.3) | China | Retrospective | 60 severecases | 57 Range (26-97) | 52 (86.6%) | 9 (15%) | 2 (3.3%) | 0 | Huang M. et al2020 |
Lopinavir +Ritonavir 99(100%) | China | Prospective | 99 | 58 Range (49-68) | NA | 10 (10.1%) | 78 (78.8%) | 19 (19.2%) | Cao B. et al2020 |
Thalidomide Methylprednisolone Ofloxacin Oseltamivir Lopinavir +Ritonavir | China | Casereport | 1 | 45-year-oldwoman | 1 (100%) | 1 (100%) | 1 (100%) | 0 | Chengshui Chen2020 |
Lopinavir +Ritonavir Umifenovir 249(100%) Corticosteroid(22%) | China | Retrospective | 249 | 51 | 22 (8.8%) | NA | 215 (86.3%) | 2 (0.8%) | Jun Chen et al2020 |
Oseltamivir, Ganciclovir,Lopinavir + Ritonavir 75(76%) Antibiotics 45(45%) Glucocorticoid 19(19%) Immunoglobulin 27(27%) | China | Retrospective | 99 | 55.5 | 2 (2%) | 17 (16.8%) | 31 (31%) | 11 (11%) | Chen N et al2020 |
Lopinavir + Ritonavir 221(75.9%) Interferon α2b 132(45.4%) Recombinant cytokine genederived protein 55 (18.9%) Umifenovir 50(17.2%) Chinese Medicine 281(96.6%) Glucocorticoids 67(23%) Oseltamivir 1(0.3%) Chloroquine 2(0.7%) | China | Retrospective | 291 | 46 | NA | NA | 159 (54.6%) | 2 (0.7%) | Chen X et al 2020 |
Antibiotics 637(58.0%) Oseltamivir 393(35.8%) Antifungal 31(2.8%) Glucocorticoids 204(18.6%) | China | Retrospective | 1099 | 47 | 55 (5.0%) | 67 (6.1%) | 64 (5.8%) | 15 (1.4%) | Guan W. et al2020 |
Antivirals 329(77%) Antibiotics 239(56%) Glucocorticoids 119(28%) Immunoglobulin 68(16%) | China | Retrospective | 450 | NA | NA | 95 (21.1%) | 195 (43.3%) | 35 (7.6%) | Liang B et al 2020 |
Oseltamivir 7(13.7%) Interferon 51(100%) Lopinavir + Ritonavir 51(100%) Thymopentin 48(94.1%) Traditional Chinesemedicine | China | Retrospective | 51 | 45 | 7 (13.7%) | 6 (11.7%) | 50 (98%) | 1 (1.9%) | liu lei and Gao Jian-ya 2020 |
Antiviral 46(100%) Antifungal 5(10.9%) Budesonide 2(4.4%) Interferon alpha 43(93.5%) | China | Retrospective | 46 | 22.5 Range (10-35) | 9 (20%) | 9 (20%) | 36 (78.3%) | 0 | Liao J et al 2020 |
Lopinavir +Ritonavir Azithromycin Ceftriaxone Tazobactam Levofloxacin | SouthKorea | Casereport | 1 | 54-year-oldman | 0 | 0 | 1 (100%) | 0 | Lim J et al 2020 |
Lopinavir 10(100%) Interferon α2b 10(100%) Immunoglobulin 2(20%) Methylprednisolone 2(20%) | China | Retrospective | 10 | 42 Range (34-50) | 3 (30%) | 5 (50%) | 7 (70%) | 0 | Liu F et al2020 |
Antibiotic 55(86%) Antiviral 64(100%) Traditional Chinese medicine13 (20%) Immunoglobulin 23(36%) Thymosin 33(52%) corticosteroids 7(11%) | China | Retrospective | 64 Medicalstaff | 35 | 0 | 0 | 34 (53%) | 0 | Liu J et al 2020 |
Ribavirin 1(16.6%) Oseltamivir 6(100%) Glucocorticoids4 Immunoglobulin 1(16.6%) | China | Retrospective | 6 | 3 Range (1-7) | 1 (16.6%) | 1 (16.6%) | 6 (100%) | 0 | Liu W et al2020 |
Antibiotics 106(97.2%) Antivirals 107(98.2%) Glucocorticoid therapy 72(66.1%) immunoglobulin 61(56.0%) | China | Retrospective | 109 | 55 | NA | 28 (25.7%) | 78 (71.6%) | 31 (28.4%) | Liu Y et al 2020 |
Lopinavir + Ritonavir 10(100%) Antibiotics 10(100%) Interferon 3(30%) Methylprednisolone 3(30%) | China | Retrospective | 10 | 54 Range (27 -64) | 0 | 0 | 5 (50%) | 0 | Lo IL et al2020 |
Lopinavir + Ritonavir 27(17.4%) Umifenovir 31(20.0%) Interferon 30(19.4%) Thymalfasin 11(7.1%) Immunoglobulin 9(5.8%) Corticosteroid 79(51%) Immune enhancer 14(9%) | China | Retrospective | 155 | 54 Range (42-66) | NA | 36 (23.2%) | 70 (45.2%) | 22 (14.1%) | Mo P et al2020 |
Oseltamivir 124(89.9%) Moxifloxacin 89(64.4%) Ceftriaxone 34(24.6%) Azithromycin 25 (18.1%)Glucocorticoid 62 (44.9%) | China | Retrospective | 138 | 56 Range (22-92) | 36 (26.1%) | 32 (23.1%) | 47 (34.1%) | 6 (4.3%) | Wang D et al 2020 |
Umifenovir 36(100%) Antibiotic therapy 66(98.5%) Corticosteroids 10(14.9%) | China | Retrospective | 36 | 42 Range (35-62) | NA | NA | 12 (33%) | 0 | Wang Z et al2020 |
Antibiotic therapy 66(98.5%) Corticosteroids 10(14.9%) | China | Retrospective | 31 | 42 Range (35-62) | NA | NA | 6 (19%) | 5 (16%) |
Antibiotics 185(98.4%) Antiviral drugs 158(84.0%) Corticosteroids 59(31.4%) | China | Retrospective | 188 | 51.9 Range (21-83) | 50 (26.6%) | NA | 145 (77.1%) | 43 (22.9%) | Wu C et al 2020 |
Oseltamivir Cefoselis Glucocorticoid | China | Casereport | 1 | 41-year-oldman | 1 (100%) | 1 (100%) | 1 (100%) | 0 | Wu F et al 2020 |
Oseltamivir 38(55.1%) Moxifloxacin, Ceftriaxone,Azithromycin, Tigecycline Linezolid 31(44.9%) Methylprednisolone 6(8.7%) | China | Retrospective | 69 | 57 Range (43-69) | NA | 5 (7.2%) | 4 (5.8%) | 1 (1.5%) | Xu Y et al 2020 |
Oseltamivir 45(100%) Ribavirin 45(100%) Antibacterial agents 45(100%) Antifungal agents 19(42.2%) Convalescent plasma 6(13.3%) Glucocorticoids 21(46.7%) Immunoglobulin 28(62.2%) Albumin 35(77.8%) | China | Retrospective | 45 | 56.7 | 7 (15.5%) | 26 (57.7%) | 11 (24.4%) | 1 (2.2%) | Xu Y et al 2020 |
Interferon alpha 8(13%) Lopinavir+ Ritonavir 4(6%) Umifenovir + Interferon 1(2%) Lopinavir+ Ritonavir +Interferon 21 (34%) Umifenovir + Lopinavir +Ritonavir 17 (28%) Umifenovir + lopinavir +Ritonavir + Interferon 4(6%) Antibiotics 28(45%) Corticosteroid 16(26%) Gamma globulin 16(26%) | China | Retrospective | 62 | 41 | 1 (1.6%) | 1 (1.6%) | 1 (1.6%) | 0 | Xu XW et al2020 |
Methylprednisolone Moxifloxacin Lopinavir +Ritonavir Interferonalfa-2b Meropenem | China | Casereport | 1 | 50-year-oldman | 1 (100%) | 0 | 0 | 1 (100%) | Xu Z et al2020 |
Oseltamivir18(35%) Ganciclovir 14(27%) Lopinavir 7(13.5%) Antibacterial 49(94%) Glucocorticoids 30(58%) Immunoglobulin 28(54%) | China | Retrospective | 52 Criticallyill | 59.7 | 52 (100%) | 37 (71%) | 8 (15.3%) | 32 (61·5%) | Yang X et al2020 |
Oseltamivir, Umifenovir,Interferon, Lopinavir + Ritonavir 196(88.7%) Glucocorticoid 115(52%) | China | Retrospective | 221 | 55 | 44 (19.9%) | 53 (23.9%) | 42 (19.0%) | 12 (5.4%) | Zhang G et al 2020 |
Antibiotics 73(91.25%) Oseltamivir 20(25%) Ribavirin, ganciclovir orPeramivir 47 (58.75%) Umifenovir 49(61.25%) Antifungal 10(12.50%) Immunoglobin 36(45%) Corticosteroids 29(36.25%) Interferon 70(87.50%) Lopinavir + Ritonavir5(6.25%) | China | Retrospective | 80 | 53 | 3 (3.75%) | 8 (10%) | 47 (58.75%) | 0 | Zhang JC et al 2020 |
Antibiotics 181(95%) Lopinavir + Ritonavir 41(21%) Corticosteroids 57(30%) Immunoglobin 46(24%) | China | Retrospective | 191 | 56 | 50 (26%) | 58 (30.3%) | 137 (71.7%) | 54 (28.2%) | Zhou F et al2020 |
Lopinavir + Ritonavir 16(80%) Umifenovir 13(65%) Interferon 5(25%) Ribavirin 1(5%) Antibiotic therapy 17(85%) Glucocorticoids 5(25%) Immunoglobulin 6(30%) Thymosin alpha1 4(20%) Chinese traditional medicine20 (100%) | China | Retrospective | 20 | 43.2 | 1 (5%) | 2 (10%) | 14 (70%) | 0 | Ziying Lei et al2020 |
Umifenovir 3(100%) Methylprednisolone 1(33.3%) Ribavirin 2(66.6%) Immunoglobin 1(33.3%) Moxifloxacin 3(100%) Oseltamivir 2(66.6%) Azithromycin 1(33.3%) | China | CaseReport | 3 Familymembers | Father Kidney transplantrecipient 49 Mother49 Son24 | 1 (33.3%) | 1 (33.3%) | 3 (100%) | 0 | Song Chen et al 2020 |
Umifenovir 16(100%) Lopinavir + Ritonavir 16(100%) Immunoglobulin 11(68.8%) Corticosteroid 1 (6.2%) Antibacterial agents 9(56.3%) | China | Retrospective | 16 | 41.8 | Patients who need ICUadmission were excluded from study | Patients who need MV wereexcluded from study | 15 (94%) | NA | Lisi Deng et al2020 |
Lopinavir + Ritonavir 17(100%) Immunoglobulin 13(76.5%) Corticosteroid 7(41.2%) antibacterial agents 12(70.6%) | China | Retrospective | 17 | 47.25 | Patients who need ICUadmission were excluded from study | Patients who need MV wereexcluded from study | 9 (52·9%) | NA |
Lopinavir + Ritonavir 34(100%) interferon- ɑ 2b(100%) | China | Retrospective | 34 | 40.5 | NA | NA | 19 (55.9%) | NA | Zhen Zhu et al2020 |
Umifenovir 16(100) interferon- ɑ 2b(100%) | China | Retrospective | 16 | 26.5 | NA | NA | 16 (100%) | 0 |
Interferon alfa 36(100%) Lopinavir + Ritonavir 14(39%) | China | Retrospective | 36 | 8.3 Range (0–16) | 0 | 0 | 36 (100%) | 0 | Haiyan Qiu et al2020 |
Hydroxychloroquine 79(93.7%) Azithromycin 79(93.7%) Ceftriaxone 6(7.5%) Immunosuppressive 4(5%) NSAIDs 2(2.5%) | France | Prospective | 80 | 52.5 | 3 (3.8%) | 12 (15%) | 65 (81.3%) | 1 (1.2%) | Philippe Gautretet al 2020 |
Corticosteroid 107(52.7%) Umifenovir 47(23.2%) Lopinavir + Ritonavir 36(16.1%) Interferon alfa 48(23.6%) Thymalfasin 16(7.9%) Immunoglobulin 11(5.4%) | China | Retrospective | 203 | 54 | NA | 39 (19.2%) | 177 (87.1%) | 26 (12.8%) | TieLong Chen et al2020 |
Lopinavir + Ritonavir 34(100%) Antibiotic therapy 34(100%) Glucocorticoid 16(47.1%) Immunoglobulin 14(41.2%) | China | Retrospective | 34 Undergoing surgeries duringCOVID-19 infection | 55 | 15 (44.1%) | 12 (35.2%) | 27 (79.4%) | 7 (20.6%) | ShaoqingLei et al2020 |
Oseltamivir, Umifenovir,Lopinavir + Ritonavir 236(86%) Glucocorticoid 217(79%) Antibiotics 249(91%) Immunoglobulin 54(20%) Interferon 89(32%) | China | Retrospective | 274 | 62 | NA | 119 (43%) | 161 (58.7%) | 113 (41.2%) | Tao Chen et al2020 |
Moxifloxacin 148 (65.78%) Ribavirin 71 (31.56%) Umifenovir 133(59.11%) Oseltamivir 138 (61.33%) Methylprednisolone 100(44%) | China | Retrospective | 225 | 50 | NA | NA | 20 (8.8%) | 2 (0.89%) | Ruoqing L et al2020 |
Antiviral treatment 78(91.8%): Umifenovir 51(60%) Lopinavir + Ritonavir 11(12.9%) Oseltamivir 9(10.6%) Paramivir 6(7.1%) Ganciclovir 5(5.9%) Ribavirin 4(4.7%) Meropenem 38(44.7%) Imipenem/cilastatin 1(1.2%) Moxifloxacin 40(47.1%) Levofloxacin 4(4.7%) Linezolid 18(21.2%) Vancomycin2(2.4%) Teicoplanin 2(2.4%) Tigecycline 2(2.4%) Piperacillin/Tazobactam 9(10.6%) Ceftriaxone sodium 3(3.5%) Cefoperazone/sulbactam 2(2.4%) Ceftazidime tazobactam 2(2.4%) Glucocorticoids 65(76.5%) Interferon 33(38.8%) Immunoglobulin therapy 38(44.7%) | China | Retrospective | 85 Fatalcases | 65.8 | NA | 79 (93%) | 0 | 85 (100%) | Yingzhen Du etal |
Carbapenem antibiotic 4(12%) Cephalosporins 7(21%) Macrolide antibiotic 18(55%) Penicillin antibiotic 23(70%) Other antibiotic 2(6%) Dexamethasone 28(85%) Lopinavir + Ritonavir 27(82%) Hydroxychloroquine 26(79%) Tocilizumab 4(12%) | Italy | Prospective | 33 Critically illpatients | 64 Range (59 –72) | 33 (100%) | 20 (60.6%) | 9 (27.2%) | 1 (3%) | Simone Piva et al2020 |
Interferon-a2b 42(62.7%) Ganciclovir 24(32.9%) Lopinavir + Ritonavir 61(83%) Oseltamivir 34(46.6%) Chinese traditional medicine20 (27.4%) Glucocorticoid 58(79.5%) Immunoglobulin 43(58.9%) | China | Retrospective | 73 | 67 | NA | 22 (30.1%) | 26 (35.6) | 21 (28.8) | Xiao Tang et al2020 |
Moxifloxacin Lopinavir +Ritonavir | China | Casereport | 1 | 50-years-old haemodialysispatient | NA | NA | 1 | 0 | Bin Tang et al 2020 |
Remdesivir 7(29.1%) Hydroxychloroquine 1(4.1%) Lopinavir + Ritonavir 1(4.1%) | USA | Retrospective | 24 Critically illpatients | 64 Range (23-97) | 24 (100%) | 18 (75%) | 5 (21%) | 12 (50%) | Pavan K et al2020 |
Lopinavir + Ritonavir,Oseltamivir, Umifenovir, Interferon 125(100%) Antibiotic therapy 79(63.2%) Glucocorticoids 35(28.0%) immunoglobulin 24(19.2%) | China | Retrospective | 125 | 38.76 | 19 (15.2%) | 4 (3.2%) | 47 (37.6%) | 0 | Ruirui Wang et al2020 |
Corticosteroid 64(56.6%) Umifenovir 55(48.7%) Ribavirin 19(16.8%) | China | Retrospective | 113 | 52 Range (43-63) | NA | 18 (15.9%) | 69 (61.1%) | 2 (1.8%) | Kaijin Xu et al2020 |
Ceftriaxone Amoxicillin/clavulanate | Taiwan | Casereport | 1 | 55-year-oldwoman | 0 | 0 | 1 (100%) without antiviraltreatment | 0 | Shao-Chung Chenget al 2020 |
Moxifloxacin Umifenovir Tocilizumab | China | Casereport | 1 With multiplemyeloma | 60-year-oldman | 1 | 0 | 1 (100%) | 0 | Xuhan Zhang et al2020 |
Oseltamivir Hydroxychloroquine Lopinavir +ritonavir | Iran | Casereport | 1 | 44-year-oldmale | NA | NA | NA the patient becameasymptomatic after treatment with Lopinavir +ritonavir | 0 | Ali Asadollahi-Amin et al2020 |
Trimethoprim/sulfamethoxazole Moxifloxacin Lopinavir +ritonavir Gamma-globulin | China | CaseReport | 1 Renal TransplantRecipient | 29-years-oldmale | NA | NA | 1 (100%) | 0 | Ling Ning et al2020 |
Interferon 7(88%) Lopinavir + ritonavir 7(88%) Ribavirin 2(25%) Oseltamivir 1(12.5%) Adenosine(12.5%) Umifenovir 1(12.5%) Levofloxacin 4(50%) Moxifloxacin 3(38%) Ceftazidime 1(13%) | China | Prospective | 8 | 22 Range (16-23) | 0 | 0 | 4 (50%) | 0 | Lei Huang et al2020 |
Corticosteroids 341(62.2%) Lopinavir + Ritonavir 164(29.9%) Umifenovir 401(73.2%) Oseltamivir 221(40.3%) Ribavirin 29(5.3%) Interferon α 168(30.7%) Immunoglobulin 213(38.9%) | China | Retrospective | 548 | 60 Range (48-69) | NA | 103 (18.7%) | 287 (52.7%) | 90 (16.5%) | Xiaochen Li et al2020 |
Umifenovir 55(100%) Ribavirin 55(100%) Interferon-α2b 55(100%) Traditional Chinese medicine34 (61.8%) Methylprednisolone 21(38.1%) | China | Retrospective | 55 | 59 Range (29-77) | NA | NA | 45 (81.8%) | 0 | Changcheng Zheng et al2020 |
Levofloxacin 17(35%) Ceftriaxone 22(46%) Azithromycin 10(21%) Linezolid 9(18.8%) other beta-lactams 15(31.3%) Lopinavir + Ritonavir 45(93.8%) Steroids 17(35.4%) Tocilizumab 2(4.2%) Chloroquine 45(93.8%) Interferon 41(85.4%) | Spain | Prospective | 48 ICUpatients | 67 Range (53-74) | 48 (100%) | 45 (93.8%) | 13 (27%) | 6 (15%) | Helena Barrasa et al202060 |
Interferon-α 1b 12(100%) Lopinavir + Ritonavir 8(66%) Ribavirin 2(16%) | China | Retrospective | 12 Paediatricpatients | 14.5 Range (0.64-17) | 0 | NA | NA All patients relieved thesymptom four days aftertreatment | 0 | Juan Chen et al2020 |
Oseltamivir, Umifenovir,Ganciclovir, Lopinavir, Ritonavir(98.53%) Moxifloxacin, Levofloxacin,Cephalosporins (97.02%) Albumin infusion(25.98%) Glucocorticoid(25.00%) | China | Retrospective | 204 | 49 Range (34-62) | NA | 10 (4.90%) | 134 (65.69%) | 26 (12.75%) | Ruyuan He et al2020 |
Hydroxychloroquine Tocilizumab | USA | Casereport | 1 OnDurable LVADSupport | 70-year-oldmale | 1 (100%) | 1 (100%) | 0 | 1 (100%) patient developed severeARDS | Vinh Q et al 2020 |
Lopinavir + ritonavir 4(80%) Interferon alfa-1b 3(60%) Favipiravir 2(40%) Umifenovir 1(20%) Darunavir 1(20%) Convalescent plasmatransfusion 5 (100%) methylprednisolone 5(100%) | China | Caseseries | 5 Critically ill patients withsevere ARDS | Range (36-65) | 5 (100%) | 5 (100%) | 3 (60%) Patients were on antiviralagents and improved after starting convalescent plasma transfusion | 0 | Chenguang Shen et al2020 |
Umifenovir 3(75%) Lopinavir+ Ritonavir 4(100%) Interferon 3(75%) Albumin, Zadaxin,Immunoglobulin, Antibacterial, Methylprednisolone, Oseltamivir,Caspofungin, Voriconazole 1(25%) Ribavirin 2(50%) Convalescent plasma 4(100%) | China | Casereports | 4 | Range (31-73) | 3 (75%) | 3 (75%) | 3 (75%) Patients were on antiviralagents and improved after starting convalescent plasma transfusion | 0 | Bin Zhang et al2020 |
Oseltamivir or Peramivir 17(100%) Antibiotic 14(82.4%) Glucocorticoid 9(52.9%) The study done on H7N9patients not COVID-19patients. | China | Prospective | 17 H7N9patients | 62.8 | NA | 14 (82.4%) | NA | 3 (17.6%) | Chen J et al2020 |
Antibiotics 82(100%) Corticosteroids29(35.3%) Antivirals 82(100%) | China | Retrospective | 82 Fatalcase | 72.5 | 14 (17.1%) | 33 (40.2%) | 0 | 82 (100%) | Bicheng Zhang et al 2020 |
Remdesivir 53(100%) 40 (75%) received 10-daycourse 10 (19%) received 5-9-daycourse 3 (6%) less than 5-daycourse | USA 22 Japan 9 Italy12 Austria1 France4 Germany2 Netherlands 1 Spain 1Canada 1 | Prospective | 53 | 64 Range (23-82) | NA | 30 (57%) | 25 (47%) | 7 (13%) | Jonathan Grein et al2020 |
Hydroxychloroquine Cefepime Remdesivir Methylprednisolone | USA | Casereport | 1 | 40-year-old-male | 1 (100%) | 1 (100%) | After initiation ofRemdesiviris progressing toward discharge | 0 | Emily Hillaker etal 2020 |